



**Proceedings and
abstracts book**



SPONSORS

DIAMOND PLUS

DNDi

Drugs for Neglected Diseases *initiative*
Iniciativa Medicamentos para Enfermedades Olvidadas
Iniciativa Medicamentos para Doenças Negligenciadas

DIAMOND



GOLD



THE **END** FUND | ENDING
NEGLECTED
DISEASES

SYMPOSIA



BILL & MELINDA
GATES foundation



care®



Global Health Strategies



LIVERPOOL SCHOOL
OF TROPICAL MEDICINE
Since 1898



PATH



World Health
Organization


OTHER



UNIVERSIDAD
DE ANTIOQUIA
Facultad de Medicina



PECET
Programa de Estudio y Control de Enfermedades Tropicales



Ministério da Saúde
FIOCRUZ
Fundação Oswaldo Cruz



Fundación
Universidad
de Antioquia



Tropical Medicine and
Infectious Disease
an Open Access Journal by MDPI



IDDO
INFECTIOUS DISEASES DATA OBSERVATORY



ThermoFisher
SCIENTIFIC



PARASITE



El conocimiento
es de todos Minciencias



SUS
MINISTÉRIO DA
SAÚDE



PAHO



PANAFOTSA
Pan American Center for Foot-and-Mouth
Disease and Veterinary Public Health



CIDEPRO
INNOVACIÓN PARA LA SALUD Y EL
BIENESTAR DE LAS COMUNIDADES



© CIDEPRO Colombia

ISSN:

PECET, Universidad de Antioquia
Sede de Investigacion Universitaria -SIU-
Calle 62 # 52 – 59, lab 632

First edition: August 23, 2022

Text correction: Sara Maria Robledo

Design and layout: Valeria Velez Wolff

Made in Colombia

Partial or total reproduction is authorized by any mean or any purpose by quoting the respective source.

The content of the work corresponds to the right of expression of the authors and do not compromise the institutional position of the University of Antioquia, PECET and/or CIDEPRO Colombia.

Medellin, Colombia.



SCIENTIFIC AND ORGANIZING COMMITTEE

Ivan Dario Velez

Chair

PECET Colombia – University of Antioquia

Jorge Alvar

Co-chair

DNDi

Sara Robledo

PECET Colombia – University of
Antioquia

Felix Tapia

Central University of Venezuela

Alexis Mendoza

Central University of Venezuela

Gabriela Delgado

Universidad Nacional de Colombia

Nancy Saravia

CIDEIM

Carlos Muskus

PECET Colombia – University of
Antioquia

Carlos Costa

Federal University of Piauí

Felipe Guhl

Andes University

Ana Cristina Patiño

PECET Colombia – University of
Antioquia

Elisa Cadavid

PECET Colombia – University of
Antioquia



Content

1. WELCOME TO THE WORLDLEISH7.....	7
2. GENERAL SCHEDULE.....	9
3. SYMPOSIUMS	11
S1. ROLE OF ASYMPTOMATICS IN THE TRANSMISSION OF LEISHMANIASIS, SLEEPING SICKNESS AND CHAGAS DISEASE	12
S2. NEW VACCINES AND IMMUNOTHERAPIES FOR CANINE LEISHMANIASIS.....	16
S3. EMERGING FOCI AND CHANGING EPIDEMIOLOGY OF LEISHMANIASIS	21
S4. ELIMINATING VL AS A PUBLIC HEALTH PROBLEM IN THE WHO SOUTH-EAST ASIA REGION: THE LAST MILE CHALLENGES AND OPPORTUNITIES THROUGH THE NEW REGIONAL STRATEGY	28
S5. INFLAMASOMES AND Leishmania	38
S6. PATHOGENESIS OF KALA-AZAR.....	44
S7. INNOVATION IN R&D TO CONTRIBUTE TO VL ELIMINATION	54
S8. SAND FLY SALIVA AND IMMUNE RESPONSE OF BITTEN HOSTS	59
S9. ELIMINATING VL IN INDIA: THE LAST MILE CHALLENGES AND OPPORTUNITIES	66
S10. NEW TRENDS IN THE DIAGNOSIS OF CHAGAS DISEASE.....	75
S11. NEW INSIGHTS IN POSTTRANSCRIPTIONAL REGULATION IN Leishmania: IMPLICATIONS IN THE PARASITE DEVELOPMENT AND DISEASE CONTROL	84
S12. VL-HIV COINFECTION	94
S13. "ATYPICAL" CUTANEOUS LEISHMANIASIS	99
S14. EPIDEMIOLOGY OF LEISHMANIASIS IN AMERICA.....	109
S15. ANIMAL MODELS FOR VISCERAL LEISHMANIASIS: SUITABILITY AND APPLICATIONS	120
S16. DRUG RESISTANCE AND TREATMENT FAILURE IN LEISHMANIASIS: A 21ST CENTURY CHALLENGE	129
S17. VL ELIMINATION AS A PUBLIC HEALTH PROBLEM IN INDIA	136



WORLD LEISH7

S18. VECTOR COMPETENCE AND Leishmania-SAND FLY INTERACTIONS.....	142
S19. DRUG TARGET IDENTIFICATION.....	150
S20. LEISHMANIASIS VACCINE: PAST, PRESENT AND FUTURE	158
S21. NEW GUIDELINE FOR THE TREATMENT OF LEISHMANIASIS IN THE AMERICAS: WHAT HAS CHANGED?	169
S22. MOLECULAR PATHOLOGY AND STRATIFICATION OF LEISHMANIASIS.....	172
S23. FUTURE PROSPECTS IN THE TREATMENT OF CUTANEOUS LEISHMANIASIS FORM.....	179
S24. LEISHMANIASIS AND MOVEMENT: IMPORTED LEISHMANIASIS BY TRAVELERS AND MIGRANTS.....	187
S25. BIOMARKERS FOR DIAGNOSIS OF LEISHMANIASIS.....	193
S26. CELL BIOLOGY AND Leishmania INFECTION	198
S27. Leishmania EXTRACELLULAR VESICLES: IMPACT ON DISEASE PROGRESSION	204
S28. VECTOR SURVEILLANCE AND CONTROL FOR VISCERAL LEISHMANIASIS ELIMINATION.....	211
S29. A GLOBAL VISCERAL LEISHMANIASIS DATA PLATFORM	222
S30. IMMUNOPATHOGENESIS AND HOST-DIRECTED THERAPIES IN LEISHMANIASIS	228
S31. RESERVOIRS OF LEISHMANIASIS.....	234
S32. GENOMICS AND EPIDEMIOLOGICAL SURVEILLANCE.....	241
S33. EXPERIENCE WITH mHEALTH AND LEISHMANIASIS.....	251
S34. EMPOWERING PEOPLE WITH CUTANEOUS LEISHMANIASIS THROUGH INTERDISCIPLINARY RESEARCH AND COMMUNITY-BASED INTERVENTIONS (ECLIPSE)	254
S35. DATA FOR DECISION MAKING FOR VL ELIMINATION	265
S36. LEISHMANIASIS AND IMMUNOSUPPRESSION	273
S37. LEISHVET: ANIMAL LEISHMANIOSIS: IS A CHANGE OF MIND NEEDED?	282
S38. THE CUTANEOUS LEISHMANIASIS IN THE MAGHREB REGION	291



WORLD LEISH7

S39. DRUG RESISTANCE & QUIESCENCE: UNRAVELLING MECHANISMS AND EXPLOITATION FOR BETTER/NEW DRUGS	296
S40. IMMUNOLOGICAL PERSPECTIVES OF LEISHMANIASIS: BEYOND THE TH1/TH2 PARADIGM	302
S41. WHAT CAN SOCIAL SCIENCES CONTRIBUTE TO UNDERSTANDING AND ADDRESSING LEISHMANIASIS?: EXAMPLES FROM THE FIELD.....	307
S42. MUCOCUTANEOUS LEISHMANIASIS	315
S43. BRASILEISH. ANIMAL LEISHMANIOSIS: IS A CHANGE OF MIND NEEDED?	325
S44 NEW HOPE FOR LEISHMANIASIS: HOW TO COMMUNICATE TO A BROADER NON-SCIENTIFIC AUDIENCE.....	334
4. ORAL COMMUNICATION	336
4.1 CANINE LEISHMANIASIS	337
4.2 DIAGNOSIS - TREATMENT AND RESISTANCE - CLINIC	359
4.3 DRUG DISCOVERY & DEVELOPMENT.....	418
4.4 EPIDEMIOLOGY/ECOEPIDEMIOLOGY/MOLECULAR EPIDEMIOLOGY/PREVENTION AND CONTROL.....	478
4.5 IMMUNOLOGY - CELL BIOLOGY – PATHOGENESIS - VACCINES.....	547
4.6 OMICS - MOLECULAR BIOLOGY – BIOCHEMISTRY - OTHERS.....	633
4.7 SOCIAL INNOVATION - IMPLEMENTATION RESEARCH - OPERATIVE RESEARCH	701
4.8 VECTORS & RESERVOIRS.....	727
5. POSTER	753
5.1 CANINE LEISHMANIASIS	754
5.2. DIAGNOSIS-TREATMENT AND RESISTANCE-CLINIC.....	827
5.3. DRUG DISCOVERY & DEVELOPMENT.....	962
5.4. EPIDEMIOLOGY – ECOEPIDEMIOLOGY - MOLECULAR EPIDEMIOLOGY - PREVENTION AND CONTROL.....	1035
5.5. IMMUNOLOGY - CELL BIOLOGY – PATHOGENESIS - VACCINES.....	1088

The logo for 'World Leish7' features the word 'WORLD' in blue, with a globe icon integrated into the letter 'O'. Below it is a blue fly icon, and the word 'LEISH7' is in red and green. The page is decorated with colorful abstract shapes like circles and concentric lines in blue, red, green, and yellow.

5.6 OMICS - MOLECULAR BIOLOGY – BIOCHEMISTRY - OTHERS.....	1207
5.7. SOCIAL INNOVATION - IMPLEMENTATION RESEARCH - OPERATIVE RESEARCH	1367
5.8 VECTORS & RESERVOIRS.....	1392
6. LIST OF CHAIR, CO-CHAIR & SPEAKERS.....	1470
7. LIST OF PARTICIPANTS	1480



1. WELCOME TO THE WORLDDLEISH7



WORLD LEISH7

Every four years, leishmaniacs from around the world gather in WorldLeish to discuss the latest advancements around these neglected tropical diseases and the seventh version was not an exception. In 2022, we had the participation of around 700 people, from 47 countries. Also, we had a great response from 536 students and professionals from around the world who sent us their abstracts to be part of the event as a poster or oral communications presentation and we are glad to say that we counted 195 oral presentations and 341 posters.

The experience and knowledge of the 210 speakers enriched the 44 Symposia, 8 Round Tables, 4 Special Meetings, 5 Plenary talks and 4 Successful stories that took place in those 6 days.

For Colombia and specifically the University of Antioquia, it was an honor to be the host of this Congress. And, for PECET, is a recognition for its almost 40 years of effort, research and hard work to treat leishmaniasis.

I would like to express my gratitude for your participation in this seventh version of the congress. Thanks to the knowledge and contributions, of all participants, it has been a complete success.

We know that it was not easy at all, however seeing all of you in Cartagena filled us with deep pride for the great challenge undertaken and the achievement reached.

May these events strengthen our "leishmaniac" spirit and recharge us to continue working in favor of this NTD.

Thank you very much.

With the expression of my admiration and respect.



Ivan Dario Vélez
Chair WorldLeish7



2. GENERAL SCHEDULE

WORLD LEISH7

MONDAY August 1st	Time	TUESDAY August 2nd	WEDNESDAY August 3rd	THURSDAY August 4th	FRIDAY 27 August 5th	Time	SATURDAY August 6th	
		REGISTRATION	REGISTRATION	REGISTRATION	REGISTRATION		REGISTRATION	
	7:00 - 8:00	REGISTRATION	REGISTRATION	REGISTRATION	REGISTRATION			
	8:00 - 9:00	PLENARY TALK #1	PLENARY TALK #2	PLENARY TALK#3	PLENARY TALK #4	8:30 - 9:30	PLENARY TALK #5	
	9:00 - 9:30	SUCCESSFUL STORY #1	SUCCESSFUL STORY #2	SUCCESSFUL STORY #3	SUCCESSFUL STORY #4	9:30 - 10:00	COFFEE BREAK	
	9:30 - 10:00	COFFEE BREAK					10:00 - 11:30	SPECIAL MEETING #4
	10:00 - 11:30	SATELITE SYMPOSIUMS (sessions 1 - 5)	SATELITE SYMPOSIUMS (sessions 12-16)	SATELITE SYMPOSIUMS (sessions 23-27)	SATELITE SYMPOSIUMS (sessions 33 -38)		AWARDS	
	11:30 - 13:00	SATELITE SYMPOSIUMS (sessions 6 -11)	SATELITE SYMPOSIUMS (sessions 17 - 22)	SATELITE SYMPOSIUMS (sessions 28 - 44) SPECIAL MEETING #2	SATELITE SYMPOSIUMS (sessions 39 - 44)	11:30 - 12:00.		
	13:00 - 14:00	LUNCH	LUNCH	POSTER PRESENTATION Session 3	LUNCH	12:00 - 13:10	CLOSING LECTURE	
	14:00 - 15:30	SPECIAL MEETING #1	ROUND TABLE (1 - 4)	LUNCH/ FREE AFTERNOON			ROUND TABLE (5 - 8)	
14:00 - 19:00	15:30 - 16:30	ORAL COMMUNICATIONS (sessions 1 - 7)	ORAL COMMUNICATIONS (sessions 15 - 21)				ORAL COMMUNICATIONS (sessions 29 - 35)	
17:30 - 18:00	16:30 - 17:30	POSTER PRESENTATION Session 1	POSTER PRESENTATION Session 2				POSTER PRESENTATION Session 4	
	17:30 - 18:00	COFFEE BREAK	COFFEE BREAK	COFFEE BREAK			13:10 - 13:30	CLOSING REMARKS
18:00 - 19:00	18:00 - 19:00	ORAL COMMUNICATIONS (sessions 8 - 14)	ORAL COMMUNICATIONS (sessions 22 - 28)	ORAL COMMUNICATIONS (sessions 36 - 41)				
19:00 - 20:30		WELCOME RECEPTION						



3. SYMPOSIUMS



S8-02: ANTI-SALIVA ANTIBODY PRODUCTION IN NAIVE DOGS EXPOSED TO UNINFECTED *Lutzomyia longipalpis* BITES

Claudia Ida Brodskyn¹ Manuela da Silva Solcà², Yuri de Jesus Silva², Stefane C. S. Jesus¹, Amanda M. R. M. Coelho², Bruna Macedo Leite¹, Shaden Kamhawi³, Jesus Valenzuela³, Deborah Fraga^{1,2}

¹Laboratory of parasite-host interaction and epidemiology, Instituto Gonçalo Moniz – FIOCRUZ (Salvador, BA, Brazil); ²Veterinary Faculty, Federal University of Bahia (Salvador, BA, Brazil); ³Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health (Rockville, MD, United States)

Canine visceral leishmaniasis (CVL) is caused by *Leishmania infantum* and transmitted to dogs and humans by sandflies. In Brazil, *Lutzomyia longipalpis* is the primary vector of this disease. When feeding, infected sandflies inoculate metacyclic promastigote forms of *Leishmania* and their saliva and other components into the hosts. Anti-saliva antibodies were associated with increased visceral leishmaniasis severity in naturally infected dogs. Although these compounds introduced by the vector favor the establishment of *Leishmania*, the early events that occur at the bite site are not fully understood. A better understanding of these initial events is essential to the development of better therapeutics and prophylactic strategies. Studies have demonstrated that sandfly saliva promotes *Leishmania* infection. *Leishmania major* co-injected with *Lu. longipalpis* or *Phlebotomus papatasi* saliva resulted in more severe disease manifestations in mice, as reflected by larger lesions compared to animals that received only parasites. This initial observation was further supported by additional studies demonstrating the enhanced infectivity of *L. major* when co-inoculated with saliva from the sandfly *Lu. longipalpis*. Apart from antihemostatic properties, sand fly saliva promotes chemotactic activity in a variety of immune cells, such as macrophages, neutrophils, dendritic cells and lymphocytes. In addition, many other cell types, including monocytes, interact with sandfly saliva, thereby modifying inflammatory processes at

WORLD LEISH7



the blood feeding site. It has been proposed that the resulting effects on the host immune system contribute to increased parasite loads in mice exposed to sandfly bites compared to animals infected through needle injection⁷. Moreover, it has also been demonstrated that other vector-derived factors can additionally contribute to *Leishmania* infection, such as the microbiota of the vector, exosomes and the promastigote secretory gel. In recent years, our group has contributed compelling data linking the differential production of lipid mediators to inflammatory factors involved in the establishment of infection. Specific levels of lipid mediators, mainly the eicosanoids leukotriene B4 (LTB4) and prostaglandin E2 (PGE2), are important components of the inflammatory response to, and outcome of infection by intracellular pathogens. Previous in vitro studies have demonstrated the role of LTB4 as a factor that participates in parasite killing, while PGE2 was shown to favor *Leishmania* survival. More recently, lipid mediators were identified as biomarkers of cutaneous and visceral leishmaniasis severity. Anti-sandfly saliva antibodies could also represent an essential epidemiological tool to assess vector exposure in endemic areas. LJM11 and LJM17 recombinant proteins are present in the vector's saliva and have already been used for this purpose. Our goal was to follow up anti-saliva antibodies (anti-LJM11 and anti-LJM17) production in naïve dogs experimentally exposed to *Lu. longipalpis* sandflies. We also assessed the persistence of anti-saliva antibodies titers for one year, and after re-exposure to the sandfly vectors. Blood samples from the dogs were collected weekly to assess the production of anti-LJM11 and anti-LJM17 IgG by ELISA. Six healthy naïve dogs were exposed weekly to 35 *Lu. longipalpis* female sandflies until at least 80% of the female were fed. Dogs were exposed to the sandflies until anti-saliva antibody production reached a plateau and remained elevated for at least three consecutive weeks. Afterward, we ceased sandflies exposures; we followed the dogs weekly until the animals tested negative for anti-saliva antibodies for three consecutive weeks. Then, we re-exposed the dogs to the sandflies and evaluated the time-period it took for the animals to resume anti-saliva antibody production. The Reactivity Index (RI) was calculated by dividing the optical density by the cut-off point obtained in each ELISA plate to compare antibody production. Soon after the first exposures, there was an immediate increase in the production of anti-saliva antibodies (between the first and the third week).

WORLD LEISH7

On the twenty-eighth day after the first exposure (with a median of 10.5 days), all six animals showed detectable anti-saliva IgG titers. Dogs were exposed to sandflies for six to nine weeks (with a median of 52.5 days). After the initial rising of anti-saliva antibody production post-exposure, anti-saliva antibody titers fluctuated, remaining detectable for over a year. We found a statistically significant difference comparing anti-saliva antibodies titers before exposure and five weeks after the exposure ($p < 0,05$). Despite the variations in titration, four dogs remained positive for 41 weeks (290 days) on average, two animals are still positive after 460 days. After the first week of re-exposure, dogs demonstrated antibody titers rising significantly. Throughout the evaluation, there was a considerable variation in antibody production among the six animals, especially concerning the time of seroconversion, time to reach the plateau, and titer decay. Although we observed differences among the animals, we can detect a similar pattern during the follow-up. Currently, studies evaluating the cellular immune response of these animals are being carried out. We have collected peripheral blood mononuclear cells (PBMC) in different time points after exposure and re-exposure and we intend to stimulate these cells with salivary gland homogenate and measure the cytokines production with LUMINEX specific canine kit. Moreover, we will measure canine serum cytokines produced during the follow-up after exposure and re-exposure to sand flies. This experimental approach allows us to better understand the early events among vector and host after exposure to sand flies and to delineate better strategies to control infection establishment.

Keywords SANDFLY; SALIVA; ANTIBODIES; RESERVOIR

Financing PROEP IGM-FIOCRUZ N°01/2020 and Fulbright Junior Member Faculty Award

SPONSORS

DIAMOND PLUS

DNDi

Drugs for Neglected Diseases *initiative*
Iniciativa Medicamentos para Enfermedades Olvidadas
Iniciativa Medicamentos para Doenças Negligenciadas

DIAMOND



GOLD



THE **END** FUND | ENDING
NEGLECTED
DISEASES

SYMPOSIA



BILL & MELINDA
GATES foundation



care®



Global Health Strategies



LIVERPOOL SCHOOL
OF TROPICAL MEDICINE
Since 1898



PATH
Programa de Estudio y Control de Enfermedades Tropicales



World Health
Organization


OTHER



UNIVERSIDAD
DE ANTIOQUIA
Facultad de Medicina



PECET
Programa de Estudio y Control de Enfermedades Tropicales



Ministério da Saúde
FIOCRUZ
Fundação Oswaldo Cruz



Fundación
Universidad
de Antioquia



Tropical Medicine and
Infectious Disease
an Open Access Journal by MDPI



IDDO
INFECTIOUS DISEASES DATA OBSERVATORY



ThermoFisher
SCIENTIFIC



PARASITE



El conocimiento
es de todos Minciencias



SUS
MINISTÉRIO DA
SAÚDE



PAHO
Pan American
Health
Organization
World Health
Organization
Americas



PANAFOTSA
Pan American Center for Foot-and-Mouth
Disease and Veterinary Public Health



CIDEPRO
INNOVACIÓN PARA LA SALUD Y EL
BIENESTAR DE LAS COMUNIDADES